As of 2025-05-16, the Intrinsic Value of Supernus Pharmaceuticals Inc (SUPN) is 38.09 USD. This SUPN valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 32.48 USD, the upside of Supernus Pharmaceuticals Inc is 17.30%.
The range of the Intrinsic Value is 25.78 - 79.79 USD
Based on its market price of 32.48 USD and our intrinsic valuation, Supernus Pharmaceuticals Inc (SUPN) is undervalued by 17.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 25.78 - 79.79 | 38.09 | 17.3% |
| DCF (Growth 10y) | 34.40 - 102.37 | 49.95 | 53.8% |
| DCF (EBITDA 5y) | 15.56 - 26.18 | 20.20 | -37.8% |
| DCF (EBITDA 10y) | 22.14 - 35.66 | 27.93 | -14.0% |
| Fair Value | 33.13 - 33.13 | 33.13 | 2.00% |
| P/E | 23.30 - 39.91 | 33.64 | 3.6% |
| EV/EBITDA | 13.12 - 34.37 | 21.31 | -34.4% |
| EPV | 41.79 - 52.58 | 47.18 | 45.3% |
| DDM - Stable | 11.51 - 38.33 | 24.92 | -23.3% |
| DDM - Multi | 17.30 - 46.29 | 25.37 | -21.9% |
| Market Cap (mil) | 1,810.44 |
| Beta | 0.37 |
| Outstanding shares (mil) | 55.74 |
| Enterprise Value (mil) | 1,741.10 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.58% |
| Cost of Debt | 5.00% |
| WACC | 6.16% |